

eviCore revisions to Internal Coverage Criteria: Executive Summary of Changes_V2.0.2025 to the following:

- Preface, Abdomen, Pediatric Abdomen, Musculoskeletal, Pediatric Musculoskeletal Imaging Guidelines, Oncology, Pediatric Oncology, and Spine Imaging Guidelines

The following pages provide an Executive Summary of the proposed changes. Updates to criteria are not noted as being more restrictive than the previous version. eviCore describes criteria updates listed as having “no change” on clinical decision making or would lead to “more approvals”.

Copies of individual criteria documents are available, upon request.

These criteria changes will go into effect August 15, 2025.

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
General Guidelines	V2.0.2025	AB-1.0	Revised clinical evaluation to remove "within 60 days" quantifier and reworded to state "relevant" instead of "current" evaluation.	No	N/A	N/A

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Soft Tissue Mass	V2.0.2025	MS-10.1	Clarified documentation of clinical features required for soft tissue mass prior to advance imaging	Yes, More Approvals	More than 1 case per week	Rochwerger A, Mattei JC. Management of soft tissue tumors of the musculoskeletal system. Orthop Traumatol Surg Res 2018;104:S9-S17. Johnson CJ, Pynsent PB, Grimer RJ. Clinical features of soft tissue sarcomas. Ann R Coll Surg Engl. 2001;83(3):203-205.
Soft Tissue Mass	V2.0.2025	MS-10.1	Added the clinical features for soft tissue mass under the applicable imaging section for further clarification	No	N/A	NA
Lesion of Bone	V2.0.2025	MS-10.2	Removed criterion to align with clinical practice	Yes, More Approvals	More than 1 case per week	NA
References	V2.0.2025	MS-10	Added applicable cited references	No	N/A	NA
Imaging Prior to Non-Customized-to- Patient Joint Replacement Surgery/Not for Intraoperative Navigation	V2.0.2025	MS-12.3	Reformatted section in order to eliminate redundancy between this guideline and the former pre-operative joint replacement sections in the anatomical area tables	No	N/A	NA
Shoulder Elbow Wrist Hip Knee Ankle	V2.0.2025	MS-19 MS-20 MS-21 MS-24 MS-25 MS-26	Removed the pre-operative joint replacement sections from each of these guidelines in the anatomical area tables as all criteria will be found in MS-12 to align these guidelines	No	N/A	NA

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Hydronephrosis	V2.0.2025	PEDAB-20	Removed sentence stating "a current evaluation (within 60 days) would not be required for authorization" as this statement is no longer relevant based on changes to Preface and other radiology sections to remove 60 day quantifier.	No	N/A	N/A

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Soft Tissue and Bone Masses - General Considerations	V2.0.2025	PEDMS-3.1	Updated list of mass characteristics that should be included in pertinent clinical exam. Added approval of MRI for soft tissue masses >5 cm in diameter, increasing in size, painful, or deep or subfascial location.	Yes, more approvals	No	Rochwerger A, Mattei JC. Management of soft tissue tumors of the musculoskeletal system. Orthop Traumatol Surg Res. 2018;104(1S):S9-S17. doi:10.1016/j.otsr.2017.05.031. Johnson CJ, Pynsent PB, Grimer RJ. Clinical features of soft tissue sarcomas. Ann R Coll Surg Engl. 2001;83(3):203-205

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Clinical information (Preface-3.1)	2.0.2025	PRF.CL.0003.1.A	Removed information discussing x-rays not needing to be within the past 60 days.	No	N/A	N/A

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Throughout	V2.0.2025	Throughout	Minor grammar, punctuation, and spelling updates as needed throughout. Evidence discussions updated in clinically updated sections.	No	N/A	N/A
General Guidelines	V2.0.2025	ONC-1.0	Updated content to state "relevant" clinical evaluation should be performed prior to imaging, instead of "recent within 60 days"	No	N/A	N/A
General Guidelines PET Imaging in Oncology	V2.0.2025	ONC-1.0 ONC-1.4	Updated list of radiotracers to include sodium fluoride under supported radiotracers.	No	N/A	N/A
Low Grade Gliomas	V2.0.2025	ONC-2.2	Updated surveillance timeframes by grade and performance status	Yes, More Approvals	No	Nabors LB, Portnow J, Baehring J, et. al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 21, 2025 Central Nervous System Cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
High Grade Gliomas	V2.0.2025	ONC-2.3	Updated timeframe of imaging following radiation therapy. Updated surveillance imaging timeframe.	Yes, More Approvals	No	Nabors LB, Portnow J, Baehring J, et. al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 21, 2025 Central Nervous System Cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
Meningiomas (Intracranial and Intraspinal)	V2.0.2025	ONC-2.8	Added dotatate PET/CT for evaluation of inconclusive MRI or CT to confirm diagnosis	Yes, More Approvals	No	Nabors LB, Portnow J, Baehring J, et. al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 21, 2025 Central Nervous System Cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
Meningiomas (Intracranial and Intraspinal)	V2.0.2025	ONC-2.8	Updated surveillance timeframes	Yes, More Approvals	No	Nabors LB, Portnow J, Baehring J, et. al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 21, 2025 Central Nervous System Cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
Melanoma - Restaging/Recurrence	V2.0.2025	ONC-5.3	Reworded primary site to state "true scar recurrence (if re-excision suggests more than in situ disease)" to better align with NCCN language. Moved CT Neck into same box as other recurrence imaging.	No	N/A	Swetter SM, Johnson, D, Albertini MR, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2025 - January 28, 2025 Melanoma: Cutaneous, available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
Non-Melanoma Skin Cancers - Surveillance/Follow-up	V2.0.2025	ONC-5.8	Expanded indications for surveillance of Merkel cell cancer	Yes, More Approvals	No	Bordeaux J, Blitzblau R, Aasi SZ, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - January 13, 2025 Merkel Cell Carcinoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf Grabowski J, Saltzstein SL, Sadler GR, Tahir Z, Blair S. A comparison of Merkel cell carcinoma

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Ocular Melanoma	V2.0.2025	ONC-5.9	Expanded surveillance timeframe for medium risk and high risk disease	Yes, More Approvals	No	Swetter S, Johnson D, Albertini MR, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - February 11, 2025 Melanoma: Uveal, available at: https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf
Non-Small Cell Lung Cancer - Initial Work-up/Staging	V2.0.2025	ONC-8.3	Updated to allow PET/CT for initial staging of all individuals with newly diagnoses NSCLC	Yes, More Approvals	No	Riely GJ, Wood DE, Aisner DL, et al, National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2025 - January 14, 2025. Non-small cell lung cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
Non-Small Cell Lung Cancer - Initial Work-up/Staging	V2.0.2025	ONC-8.3	Updated brain imaging to include stage IB disease	Yes, More Approvals	No	Riely GJ, Wood DE, Aisner DL, et al, National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2025 - January 14, 2025. Non-small cell lung cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
Non-Small Cell Lung Cancer - Surveillance/Follow-up	V2.0.2025	ONC-8.5	Updated timeframes for restaging. Reworded indications, for clarity.	Yes, More Approvals	No	Riely GJ, Wood DE, Aisner DL, et al, National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2025 - January 14, 2025. Non-small cell lung cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
Esophageal and GE Junction Cancer - Restaging/Recurrence	V2.0.2025	ONC-9.3	Added option of including pelvis in CT imaging if there are signs/symptoms of pelvic involvement or known pelvic involvement	Yes, More Approvals	No	Ajani JA, D'Amico TA, Barzi A, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 5.2024 - December 20, 2024. Esophageal and esophagogastric junction cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Esophageal and GE Junction Cancer - Restaging/Recurrence	V2.0.2025	ONC-9.3	Updated to state PET/CT after primary chemoradiation therapy no sooner than 5 weeks post completion of rad therapy, instead of 8 weeks.	Yes, More Approvals	No	Ajani JA, D'Amico TA, Barzi A, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 5.2024 - December 20, 2024. Esophageal and esophagogastric junction cancers, available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
Breast Cancer - Initial Work-up/Staging	V2.0.2025	ONC-11.2	Updated criteria to allow MRI Breast in all newly diagnosed breast cancer or ductal carcinoma in situ.	Yes, More Approvals	No	Gradishar WJ, Moran MS, Abraham J, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 6.2024 - November 11, 2024. Breast Cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Breast Cancer - Initial Work-up/Staging	V2.0.2025	ONC-11.2	Updated PET criteria indications to include stage III N2 disease, T4 disease, and inflammatory breast cancer.	Yes, More Approvals	No	Gradishar WJ, Moran MS, Abraham J, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 6.2024 - November 11, 2024. Breast Cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Breast Cancer - Initial Work-up/Staging	V2.0.2025	ONC-11.2	Added redirect to BR-5.1 for ADH, LCIS, and ALH. Clarified stage descriptions of disease for which systemic staging is indicated.	No	N/A	N/A
Breast Cancer - Initial Work-up/Staging	V2.0.2025	ONC-11.2	Added criteria to allow approval of sodium fluoride PET/CT for evaluation of bone pain if all other imaging modalities are inconclusive for bone metastasis	Yes, More Approvals	No	Gradishar WJ, Moran MS, Abraham J, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 6.2024 - November 11, 2024. Breast Cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Breast Cancer - Restaging/Recurrence	V2.0.2025	ONC-11.3	Added criteria to allow approval of sodium fluoride PET/CT if all other imaging modalities are inconclusive for bone metastasis	Yes, More Approvals	No	Gradishar WJ, Moran MS, Abraham J, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 6.2024 - November 11, 2024. Breast Cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Breast Cancer - Surveillance/Follow-up	V2.0.2025	ONC-11.4	Clarified individuals with history of high-risk lesions	No	N/A	N/A
Soft Tissue Sarcomas - Initial Work-up/Staging	V2.0.2025	ONC-12.2	Updated initial staging to allow imaging with CT Chest and MRI of involved area for all individuals. Added additional histologies to list of indications for abdomen/pelvis imaging.	Yes, More Approvals	No	Von Mehren M, Kane III JM, Armstrong SA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - November 21, 2024. Soft Tissue Sarcoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf .
Soft Tissue Sarcomas - Initial Work-up/Staging	V2.0.2025	ONC-12.2	Added brain imaging in initial staging of specific histologies.	Yes, More Approvals	No	Von Mehren M, Kane III JM, Armstrong SA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - November 21, 2024. Soft Tissue Sarcoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf .
Soft Tissue Sarcomas - Initial Work-up/Staging	V2.0.2025	ONC-12.2	Added bone scan for additional imaging in initial work-up of leiomyosarcoma	Yes, More Approvals	No	Von Mehren M, Kane III JM, Armstrong SA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - November 21, 2024. Soft Tissue Sarcoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf .

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Soft Tissue Sarcomas - Initial Work-up/Staging	V2.0.2025	ONC-12.2	Added additional indications for the use of PET/CT in initial staging	Yes, More Approvals	No	Von Mehren M, Kane III JM, Armstrong SA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - November 21, 2024. Soft Tissue Sarcoma, available at: https://www.nccn.org/professionals/ physician_gls/pdf/sarcoma.pdf .
Soft Tissue Sarcomas - Restaging/Recurrence	V2.0.2025	ONC-12.3	Additional criterion added for baseline end of therapy evaluation with imaging mirroring that of initial work-up.	Yes, More Approvals	No	Von Mehren M, Kane III JM, Armstrong SA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - November 21, 2024. Soft Tissue Sarcoma, available at: https://www.nccn.org/professionals/ physician_gls/pdf/sarcoma.pdf .
Soft Tissue Sarcomas - Surveillance/Follow-up	V2.0.2025	ONC-12.4	Surveillance imaging timeframe for retroperitoneal, angiosarcoma, and epithelioid sarcoma updated to allow every 3 month imaging for the first 3 years. Timeframe for surveillance of desmoid tumors updated to allow imaging every 3 months for the first three years, then every 6-12 months.	Yes, More Approvals	No	Von Mehren M, Kane III JM, Armstrong SA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - November 21, 2024. Soft Tissue Sarcoma, available at: https://www.nccn.org/professionals/ physician_gls/pdf/sarcoma.pdf .
Bone Sarcomas - Initial Work-up/Staging	V2.0.2025	ONC-12.6	Added redirection to PEDONC-9.3 for osteosarcoma and PEDONC-9.4 for Ewing sarcoma and primitive neuroectodermal tumors	No	N/A	Biermann JS, Hirbe A, Agulnik M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - August 20, 2024. Bone cancer, available at: https://www.nccn.org/professionals/physician_gl s/pdf/bone.pdf .
Bone Sarcomas - Restaging/Recurrence	V2.0.2025	ONC-12.7	Added indication and imaging of suspected recurrence of atypical cartilaginous tumor	Yes, More Approvals	No	Biermann JS, Hirbe A, Agulnik M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - August 20, 2024. Bone cancer, available at: https://www.nccn.org/professionals/physician_gl s/pdf/bone.pdf .

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Bone Sarcomas - Surveillance/Follow-up	V2.0.2025	ONC-12.8	Updated surveillance to include grade I chondrosarcoma and low grade extracompartmental appendicular tumors in the more frequent imaging timeframe. Updated timeframe of imaging intra-compartmental chondrosarcoma to allow imaging range of 6-12 months	Yes, More Approvals	No	Biermann JS, Hirbe A, Agulnik M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - August 20, 2024. Bone cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf .
Benign Bone Tumors - Surveillance/Follow-up	V2.0.2025	ONC-12.12	Updated surveillance imaging timeframe for GCTB to allow timeframe range of 6-12 months	Yes, More Approvals	No	Biermann JS, Hirbe A, Agulnik M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - August 20, 2024. Bone cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf .
Pancreatic Cancer - Screening Studies for Pancreatic Cancer	V2.0.2025	ONC-13.1	EPCAM and TP53 gene mutations were added under indications for screening of individuals with family history of pancreatic cancer. BRCA2 and ATM were removed from this list and placed into their own screening indications as family history is not required to initiate screening in these individuals.	Yes, More Approvals	No	Daly MB, Pal T, AlHilli Z, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version V2.2025 - November 7, 2024. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate available at: https://www.nccn.org/professionals/physician_gls/pdf/bopp.pdf
Pancreatic Cancer - Screening Studies for Pancreatic Cancer	V2.0.2025	ONC-13.1	Added allowance for screening of individuals with CDKN2A mutation or Peutz-Jeghers syndrome to begin 10 years earlier than the youngest affected family member, if family history exists	Yes, More Approvals	No	Daly MB, Pal T, AlHilli Z, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version V2.2025 - November 7, 2024. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate available at: https://www.nccn.org/professionals/physician_gls/pdf/bopp.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Pancreatic Cancer - Screening Studies for Pancreatic Cancer Pancreatic Cancer - Suspected/Diagnosis Pancreatic Cancer - Initial Work-up/Staging Pancreatic Cancer - Restaging/Recurrence	V2.0.2025	ONC-13.1 ONC-13.2 ONC-13.3 ONC-13.4	Clarified coding of MRCP to allow 3D rendering in conjunction with the diagnostic MRI code.	No	N/A	N/A
Pancreatic Cancer - Initial Work-up/Staging	V2.0.2025	ONC-13.3	Added additional indications for PET/CT imaging	Yes, More Approvals	No	Tempero MA, Malafa MP, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - December 20, 2024. Pancreatic Adenocarcinoma, available at: https://www.nccn.org/professionals/ physician_gls/pdf/pancreatic.pdf
Pancreatic Cancer - Restaging/Recurrence Pancreatic Cancer - Surveillance/Follow-up	V2.0.2025	ONC-13.4 ONC-13.5	Added option of using MRI for abdominal imaging	Yes, More Approvals	No	Tempero MA, Malafa MP, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - December 20, 2024. Pancreatic Adenocarcinoma, available at: https://www.nccn.org/professionals/ physician_gls/pdf/pancreatic.pdf
Pancreatic Cancer - Restaging/Recurrence	V2.0.2025	ONC-13.4	Added option of PET/CT for inconclusive findings on conventional imaging	Yes, More Approvals	No	Tempero MA, Malafa MP, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - December 20, 2024. Pancreatic Adenocarcinoma, available at: https://www.nccn.org/professionals/ physician_gls/pdf/pancreatic.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Pancreatic Cancer - Restaging/Recurrence	V2.0.2025	ONC-13.4	Updated indication to allow imaging after neoadjuvant therapy, not specifically only chemoradiation	Yes, More Approvals	No	Tempero MA, Malafa MP, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - December 20, 2024. Pancreatic Adenocarcinoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
Gastrointestinal/Pancre atic Neuroendocrine Cancers - Suspected/Diagnosis, Initial Work-up/Staging, Restaging/Recurrence Bronchopulmonary or Thymic Carcinoid - Initial Staging, Restaging/Recurrence Adrenal Tumors - Initial Work-up/Staging, Restaging/Recurrence	V2.0.2025	ONC-15.2 ONC-15.3 ONC-15.4 ONC-15.6 ONC-15.7 ONC-15.10 ONC-15.11	Updated to allow option of dotatate PET/MRI where PET/CT is currently offered.	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
Gastrointestinal/Pancre atic Neuroendocrine Cancers - Suspected/Diagnosis	V2.0.2025	ONC-15.3	Initial work up updated to allow dotatate PET and diagnostic CT or MRI for specific types of neuroendocrine tumors	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
Gastrointestinal/Pancre atic Neuroendocrine Cancers - Restaging/Recurrence	V2.0.2025	ONC-15.4	MRI added as option for imaging of unresectable/metastatic disease on treatment.	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Gastrointestinal/Pancreatic Neuroendocrine Cancers - Restaging/Recurrence	V2.0.2025	ONC-15.4	Clarified wording of suspected recurrence	No	N/A	N/A
Gastrointestinal/Pancreatic Neuroendocrine Cancers - Restaging/Recurrence	V2.0.2025	ONC-15.4	Added imaging with dotatate PET for any suspected recurrence. Thus, imaging for inconclusive CT or MRI is updated to reflect use of Octreotide scan if PET is not available.	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
Gastrointestinal/Pancreatic Neuroendocrine Cancers - Surveillance	V2.0.2025	ONC-15.5	Updated size of appendix carcinoid for which surveillance imaging is not routinely indicated - from ≤ 2 to < 1	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
Gastrointestinal/Pancreatic Neuroendocrine Cancers - Surveillance	V2.0.2025	ONC-15.5	Surveillance imaging timeframes updated; added option of MRI imaging to stomach, large and small intestine neuroendocrine tumors.	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
Bronchopulmonary or Thymic Carcinoid - Initial Staging, Restaging/Recurrence	V2.0.2025	ONC-15.6 ONC-15.7	Updated to allow option of MRI imaging instead of CT abdomen	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Bronchopulmonary or Thymic Carcinoid - Surveillance	V2.0.2025	ONC-15.8	Added additional option of imaging CT Abdomen with contrast. Updated surveillance timeframes. Added CT Chest imaging for measurable metastatic disease on maintenance therapy.	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/ professionals/physician_gls/pdf/neuroendocrine. pdf
Bronchopulmonary or Thymic Carcinoid - Surveillance	V2.0.2025	ONC-15.8	Added additional indication for imaging of asymptomatic lung or thymus distant metastasis on observation alone.	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/ professionals/physician_gls/pdf/neuroendocrine. pdf
Adrenal Tumors - Initial Work-up/Staging	V2.0.2025	ONC-15.10	Additional imaging indication added - hypercortisolemia with additional risk factors	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/ professionals/physician_gls/pdf/neuroendocrine. pdf
Adrenal Tumors - Restaging/Recurrence	V2.0.2025	ONC-15.11	Additional indications added for FDG PET/CT	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/ professionals/physician_gls/pdf/neuroendocrine. pdf
Adrenal Tumors - Restaging/Recurrence	V2.0.2025	ONC-15.11	Additional indication for dotate PET added (to assess candidacy for PRRT)	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/ professionals/physician_gls/pdf/neuroendocrine. pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Adrenocortical Carcinoma	V2.0.2025	ONC-15.13	Added option of FDG PET/CT for initial imaging of adrenocortical carcinoma. Removed mention of solitary adrenal mass >4 cm under other indications for PET as this study is now offered to all for initial staging.	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
Adrenocortical Carcinoma	V2.0.2025	ONC-15.13	Updated contrast options for surveillance imaging	No	N/A	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
Colorectal Cancer - Restaging/Recurrence	V2.0.2025	ONC-16.3	Clarified signs of suspected recurrence (signs and symptoms, elevated CEA)	No	N/A	Benson III AB, Venook AP, Adam M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - February 6, 2025. Colon cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf .
Renal Cell Cancer (RCC) - Restaging/Recurrence	V2.0.2025	ONC-17.3	Corrected CPT code typo	No	N/A	N/A
Transitional Cell Cancer - Initial Work- up/Staging	V2.0.2025	ONC-18.2	Updated criteria to allow MRI Pelvis to be performed as additional imaging in initial staging of sessile or high-grade tumors	Yes, More Approvals	No	Flaig TW, Spiess PE, Abern M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 5.2024 - October 28, 2024. Bladder cancer, available at: https://www.nccn.com/professionals/physician_gls/pdf/bladder.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Transitional Cell Cancer - Initial Work- up/Staging	V2.0.2025	ONC-18.2	Added criteria to allow approval of bone scan, MRI, or PET/CT for evaluation of suspected bone metastasis in select clinical circumstances.	Yes, More Approvals	No	Flaig TW, Spiess PE, Abern M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 5.2024 - October 28, 2024. Bladder cancer, available at: https://www.nccn.com/professionals/physician_gls/pdf/bladder.pdf
Transitional Cell Cancer - Initial Work- up/Staging	V2.0.2025	ONC-18.2	Added link to ONC-31.3 for suspected brain metastases	No	N/A	N/A
Transitional Cell Cancer - Restaging/Recurrence	V2.0.2025	ONC-18.3	Added additional indication for CT Chest imaging - known prior or suspected muscle invasive disease, as this aligns with the imaging recommended for initial staging.	Yes, More Approvals	No	Flaig TW, Spiess PE, Abern M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 5.2024 - October 28, 2024. Bladder cancer, available at: https://www.nccn.com/professionals/physician_gls/pdf/bladder.pdf
Transitional Cell Cancer - Surveillance/Follow-up	V2.0.2025	ONC-18.4	Updated surveillance timeframes and imaging - now indicating a timeframe range, as well as allowing for the choice of CTU or MRU (imaging as performed in initial staging). Updated low grade surveillance to allow one-time baseline imaging at the end of therapy.	Yes, More Approvals	No	Flaig TW, Spiess PE, Abern M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 5.2024 - October 28, 2024. Bladder cancer, available at: https://www.nccn.com/professionals/physician_gls/pdf/bladder.pdf
Prostate Cancer - General Considerations	V2.0.2025	ONC-19.0	Removed "within the last 60 days"	No	N/A	N/A

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Prostate Cancer - Initial Work-up/Staging	V2.0.2025	ONC-19.2	Reformatted metastatic disease indications to separate oligo- or low volume metastatic prostate cancer from diffuse metastatic prostate cancer.	No	N/A	N/A
Prostate Cancer - Initial Work-up/Staging	V2.0.2025	ONC-19.2	Updated to allow option of MRI imaging of the Pelvis for metastatic prostate cancer	Yes, More Approvals	No	Schaeffer E, Srinivas S, Adra N, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - May 17, 2024. Prostate cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf .
Prostate Cancer - Initial Work-up/Staging Prostate Cancer - Restaging/Recurrence	V2.0.2025	ONC-19.2 ONC-19.3	For inconclusive bone scan, the indicated subsequent imaging was updated to include PET/CT or PET/MRI. Sodium fluoride radiotracer included as option.	Yes, More Approvals	No	Schaeffer E, Srinivas S, Adra N, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - May 17, 2024. Prostate cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf .
Prostate Cancer - Restaging/Recurrence	V2.0.2025	ONC-19.3	Updated restaging indications to include imaging for individuals with an increase in PSA to 0.1 ng/mL or higher; individuals with undetectable PSA that become detectable, or persistent detectable PSA after prostatectomy. Also updated indicated imaging to include PET/MRI	Yes, More Approvals	No	Schaeffer E, Srinivas S, Adra N, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - May 17, 2024. Prostate cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf .
Prostate Cancer - Restaging/Recurrence	V2.0.2025	ONC-19.3	Added option of pelvic imaging with MRI to restaging while on chemotherapy or anti-androgen therapy	Yes, More Approvals	No	Schaeffer E, Srinivas S, Adra N, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - May 17, 2024. Prostate cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf .

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Testicular, Ovarian and Extragonadal Germ Cell Tumors - Initial Work-up/Staging	V2.0.2025	ONC-20.1	Added CT or MRI imaging for suspicious testicular mass on ultrasound (prior to orchiectomy).	Yes, More Approvals	No	Gilligan T, Lin DW, Adra N, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - January 17, 2025. Testicular cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf
Testicular, Ovarian and Extragonadal Germ Cell Tumors - Initial Work-up/Staging	V2.0.2025	ONC-20.1	Added redirect for suspicious pelvic masses (suspected to be ovarian in nature) to ONC-21.2	No	N/A	N/A
Testicular, Ovarian and Extragonadal Germ Cell Tumors - Surveillance	V2.0.2025	ONC-20.3	MRI imaging options added for surveillance of seminomas and non- seminomas. Updated timeframe of surveillance imaging for non- seminomas	Yes, More Approvals	No	Gilligan T, Lin DW, Adra N, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - January 17, 2025. Testicular cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf
Testicular, Ovarian and Extragonadal Germ Cell Tumors - Surveillance	V2.0.2025	ONC-20.3	Updated surveillance of stage II-III NSGCT with complete response to include chest imaging for symptoms of thoracic disease	Yes, More Approvals	No	Gilligan T, Lin DW, Adra N, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - January 17, 2025. Testicular cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf
Uterine Cancer - Initial Work-Up/Staging	V2.0.2025	ONC-22.2	Chest imaging criteria updated to allow for CT for new or worsening pulmonary symptoms in addition to findings on chest x-ray	Yes, More Approvals	No	Abu-Rustum NR, Campos SM, Arend R, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2025 - January 31, 2025. Uterine Neoplasms, available at: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Uterine Cancer - Initial Work-Up/Staging	V2.0.2025	ONC-22.2	Added lymph system imaging to initial staging studies for surgical staging or high risk histologies	Yes, More Approvals	No	Abu-Rustum NR, Campos SM, Arend R, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2025 - January 31, 2025. Uterine Neoplasms, available at: https://www.nccn.org/professionals/ physician_gls/pdf/uterine.pdf
Cervical Cancer - Surveillance	V2.0.2025	ONC-23.4	Increased surveillance timeframe range for stage I disease to include imaging for up to 3 years	Yes, More Approvals	No	Abu-Rustum NR, Campos SM, Yashar CM, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2025 - January 31, 2025. Cervical Cancer, available at: https://www.nccn.org/professionals/physician_gl s/pdf/cervical.pdf .
Anal Carcinoma - Restaging/Recurrence	V2.0.2025	ONC-24.3	Clarified that imaging for restaging is preferably the same as imaging studies used in initial staging	No	N/A	Benson III AB, Venook AP, Adam M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2025 - January 17, 2025. Anal Carcinoma, available at: https://www.nccn.org/professionals/ physician_gls/pdf/anal.pdf
Multiple Myeloma and Plasmacytomas - Suspected/Diagnosis	V2.0.2025	ONC-25.1	Reformatted to remove criteria from this section - now referring to initial work-up/staging (ONC-25.2) for this information	No	N/A	N/A
Multiple Myeloma and Plasmacytomas - Initial Work-Up/Staging	V2.0.2025	ONC-25.2	Updated to allow option of PET/CT for initial imaging of any confirmed or suspected myeloma, initial imaging of known or suspected POEMS, or known or suspected systemic light chain amyloidosis.	Yes, More Approvals	No	Kumar SK, Callander NS, Adekola K, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - September 17, 2024. Myeloma, available at: https://www.nccn.org/professionals/physician_gl s/pdf/myeloma.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Multiple Myeloma and Plasmacytomas - Initial Work-Up/Staging Multiple Myeloma and Plasmacytomas - Restaging/Recurrence	V2.0.2025	ONC-25.2 ONC-25.3	Updated imaging used to discern smoldering myeloma from active myeloma to allow whole body MRI.	Yes, More Approvals	No	Kumar SK, Callander NS, Adekola K, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - September 17, 2024. Myeloma, available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
Multiple Myeloma and Plasmacytomas - Initial Work-Up/Staging	V2.0.2025	ONC-25.2	Updated to allow additional imaging based on suspected organ involvement in the initial work-up of suspected or known systemic light chain amyloidosis	Yes, More Approvals	No	Kumar SK, Callander NS, Adekola K, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - September 17, 2024. Myeloma, available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
Multiple Myeloma and Plasmacytomas - Restaging/Recurrence	V2.0.2025	ONC-25.3	Clarified preferred imaging study for PET/CT is whole-body PET/CT	No	N/A	N/A
Multiple Myeloma and Plasmacytomas - Restaging/Recurrence	V2.0.2025	ONC-25.3	Updated to allow whole-body MRI for imaging of extra-osseous plasmacytoma response to initial therapy	Yes, More Approvals	No	Kumar SK, Callander NS, Adekola K, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - September 17, 2024. Myeloma, available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
Multiple Myeloma and Plasmacytomas - Restaging/Recurrence	V2.0.2025	ONC-25.3	Updated imaging for stem cell transplant recipients to allow whole- body MRI	Yes, More Approvals	No	Kumar SK, Callander NS, Adekola K, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - September 17, 2024. Myeloma, available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Multiple Myeloma and Plasmacytomas - Surveillance	V2.0.2025	ONC-25.4	Updated surveillance imaging to include whole-body MRI or whole-body PET/CT, using same imaging modality as performed at diagnosis, annually. Clarified that end of surveillance timeframe (at 5 years) applies only to solitary plasmacytomas.	Yes, More Approvals	No	Kumar SK, Callander NS, Adekola K, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - September 17, 2024. Myeloma, available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
Diffuse Large B Cell Lymphoma (DLBCL)	V2.0.2025	ONC-27.2	Separated treatment response indications to allow more frequent timeframe for restaging in stage II disease with extensive mesenteric disease and stages III-IV	Yes, More Approvals	No	Zelenetz AD, Gordon LI, Abramson JS, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - December 20, 2024. B-cell lymphomas, available at: https://www.nccn.org/professionals/physician_gls/pdf/B-CELL.pdf
Marginal Zone Lymphomas	V2.0.2025	ONC-27.4	Specific criteria for approval of PET/CT in suspected recurrence added	Yes, More Approvals	No	Zelenetz AD, Gordon LI, Abramson JS, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - December 20, 2024. B-cell lymphomas, available at: https://www.nccn.org/professionals/physician_gls/pdf/B-CELL.pdf
T Cell Lymphomas	V2.0.2025	ONC-27.8	Added MRI Orbits/face/neck for t-cell lymphoma of nasal cavity, oropharynx, or nasopharynx	Yes, More Approvals	No	Horwitz SM, Ansell S, Ai WZ, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 - November 11, 2024. T-cell lymphomas, available at: https://www.nccn.org/professionals/physician_gls/pdf/T-CELL.pdf
Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma	V2.0.2025	ONC-27.10	Added PET/CT for initial staging/diagnosis of all individuals	Yes, More Approvals	No	Kumar SK, Callander NS, Adekola K, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2025 - February 6, 2025. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, available at: https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
General Considerations for Stem Cell Transplant	V2.0.2025	ONC-29.1	Added additional criteria for approval of CT Chest imaging in the immediate pre-transplant period (any individual prior to undergoing allogeneic transplant). Clarified that CT of other body areas is not indicated without clinical signs or symptoms of involvement.	Yes, More Approvals	No	Alhomoud M, Chokr N, Gomez-Arteaga A, et al. Screening chest CT prior to allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2023;29(5):326.e1-326.e10. doi:10.1016/j.jtct.2023.01.029. McQuinn D, Racki L, Venkre VP, et al. Full body screening computed tomography prior to allogeneic hematopoietic stem cell transplantation: a single institution experience from an academic center. Blood. 2023;142:378-379.
Bone (Including non-Vertebral) Metastases	V2.0.2025	ONC-31.5	Added indication for imaging with either CTs or PET in individuals age 40 or older with symptomatic bone lesions and abnormal x-ray	Yes, More Approvals	No	Biermann JS, Hirbe A, Ahlawat S, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 – August 20, 2024. Bone Cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf
Spinal/Vertebral Metastases	V2.0.2025	ONC-31.6	Reworded severe pain criteria to state "and/or rapidly" worsening. Removed mention of conservative treatment.	Yes, More Approvals	No	N/A
Extrathoracic Small Cell and Large Cell Neuroendocrine Tumors	V2.0.2025	ONC-31.8	Added option of imaging the abdomen and pelvis with MR in all phases.	Yes, More Approvals	No	Bergsland E, Rose JB, Benson III AB, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - January 17, 2025. Neuroendocrine and Adrenal Tumors, available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Red Flag Indications - Cancer	V2.0.2025	SP-1.2	Removed timeframe for treatment with clinical suspicion of spinal malignancy and severe and/or worsening spinal pain to provide clarity in the guidelines	Yes, More Approvals	No	NA
Red Flag Indications - Cancer	V2.0.2025	SP-1.2	Updated language in section for known history of cancer and suspicion of spinal malignancy to provide clarity and reduce redundancy in the guidelines	No	N/A	NA

Pediatric and Special Populations Oncology Imaging Guidelines
Executive Summary
Effective Date: June 15, 2025

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Throughout	V2.0.2025	Throughout	Minor spelling, grammar, and punctuation changes as needed.	No	N/A	N/A
General Guidelines Screening Imaging in Cancer Predisposition Syndromes - General Considerations	V2.0.2025	PEDONC-1.0 PEDONC-2.1	Reworded clinical evaluation to state "relevant" instead of "recent"; removed quantifier stating "within 60 days"	No	N/A	N/A
Neurofibromatosis 1 and 2 (NF1 and NF2)	V2.0.2025	PEDONC-2.3	Added redirection bullet for adult patients with MPNST to be reviewed under ONC-12	No	N/A	N/A
Neurofibromatosis 1 and 2 (NF1 and NF2)	V2.0.2025	PEDONC-2.9	Updated timeframe for MRI imaging from every 3 years to annually	Yes, more approvals	No	Motzer RJ, Jonasch E, Agarwal N, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2025 – January 9, 2025. Kidney Cancer, available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf .
Hereditary Paraganglioma- Pheochromocytoma (HPP) Syndromes	V2.0.2025	PEDONC-2.13	Updated PET/CT indication to state dotatate as the preferred radiotracer. Added background and supporting information discussing dotatate radiotracer.	No	N/A	Taieb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019;26(11):R627-R652. doi:10.1530/ERC-19- 0165

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Acute Lymphoblastic Leukemia (ALL)	V2.0.2025	PEDONC-3.2	Added criteria to allow CT head for urgent concerns where MRI would delay care (i.e., suspected CNS bleed)	Yes, more approvals	No	Inaba H, Teachey D, Annesley C, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025-August 28, 2024, Pediatric Acute Lymphoblastic Leukemia, available at: https://www.nccn.org/ professionals/physician_gls/pdf/ped_all.pdf
CNS Tumors General Considerations	V2.0.2025	PEDONC-4.1	Updated to specify the CPT codes used for perfusion imaging	No	N/A	N/A
CNS Low Grade Gliomas (LGG)	V2.0.2025	PEDONC-4.2	Updated surveillance indication to clarify that individuals with unresected disease on observation only are included in this category	No	N/A	N/A
CNS High Grade Gliomas (HGG)	V2.0.2025	PEDONC-4.3	Added option of using whole spine imaging if requested for baseline following resection or for end of radiotherapy assessment	Yes, more approvals	No	Gajjar A, Mahajan A, Bale T, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2025 -January 17, 2025. Pediatric Central Nervous System Cancers, available at: https://www.nccn.org/ professionals/physician_gls/pdf/ped_cns.pdf
CNS High Grade Gliomas (HGG)	V2.0.2025	PEDONC-4.3	Added option of additional MR perfusion or MR spectroscopy if requested for surveillance	Yes, more approvals	No	Gajjar A, Mahajan A, Bale T, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2025 -January 17, 2025. Pediatric Central Nervous System Cancers, available at: https://www.nccn.org/ professionals/physician_gls/pdf/ped_cns.pdf
CNS High Grade Gliomas (HGG)	V2.0.2025	PEDONC-4.3	Updated surveillance imaging timeframe	Yes, more approvals	No	Gajjar A, Mahajan A, Bale T, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2025 -January 17, 2025. Pediatric Central Nervous System Cancers, available at: https://www.nccn.org/ professionals/physician_gls/pdf/ped_cns.pdf

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Medulloblastoma (MDB), Other CNS Embryonal Tumors, and Pineoblastoma	V2.0.2025	PEDONC-4.4	Updated to include MRI spine without and with contrast for postoperative evaluation if spinal disease was resected	Yes, more approvals	No	Gajjar A, Mahajan A, Bale T, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2025 -January 17, 2025. Pediatric Central Nervous System Cancers, available at: https://www.nccn.org/ professionals/physician_gls/pdf/ped_cns.pdf
Pediatric Aggressive Mature B-Cell Non- Hodgkin Lymphomas (NHL)	V2.0.2025	PEDONC-5.3	Added repeat PET or CTs to follow up Deauville 4-5 avidity on end of therapy PET	Yes, more approvals	No	Barth M, Xavier AC, Acquazzino M, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024 - September 3, 2024, Pediatric Aggressive Mature B-Cell Lymphomas, available at: https://www.nccn.org/ professionals/physician_gls/pdf/ped_b-cell.pdf
Unilateral Wilms Tumor (UWT)	V2.0.2025	PEDONC-7.2	Updated initial staging to allow option of CT Abdomen Pelvis for all individuals	Yes, more approvals	No	Balis F, Green DM, Armstrong A, et. al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024 - October 25, 2024. Wilms Tumor (Nephroblastoma), available at: https://www.nccn.org/professionals/ physician_gls/pdf/wilms_tumor.pdf
Unilateral Wilms Tumor (UWT) Bilateral Wilms Tumor (BWT)	V2.0.2025	PEDONC-7.2 PEDONC-7.3	Added criterion to allow pelvic surveillance imaging for diffuse anaplastic histology	Yes, more approvals	No	Balis F, Green DM, Armstrong A, et. al. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024 - October 25, 2024. Wilms Tumor (Nephroblastoma), available at: https://www.nccn.org/professionals/ physician_gls/pdf/wilms_tumor.pdf
Non- Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)	V2.0.2025	PEDONC-8.3	Added additional histologies in which CT Abdomen Pelvis may be performed in initial staging	Yes, more approvals	No	Von Mehren M, Kane III JM, Armstrong SA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - November 21, 2024. Soft Tissue Sarcoma, available at: https://www.nccn.org/ professionals/ physician_gls/pdf/sarcoma.pdf .
Non- Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)	V2.0.2025	PEDONC-8.3	Updated surveillance of NRSTS to allow more frequent imaging in all grades other than low grade	Yes, more approvals	No	Von Mehren M, Kane III JM, Armstrong SA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - November 21, 2024. Soft Tissue Sarcoma, available at: https://www.nccn.org/ professionals/ physician_gls/pdf/sarcoma.pdf .

Section Name	Version/ Release Number	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision- making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Non- Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)	V2.0.2025	PEDONC-8.3	Surveillance brain imaging added for angiosarcoma, alveolar soft part sarcoma, and cardiac sarcoma	Yes, more approvals	No	Von Mehren M, Kane III JM, Armstrong SA, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024 - November 21, 2024. Soft Tissue Sarcoma, available at: https://www.nccn.org/professionals/ physician_gls/pdf/sarcoma.pdf .
Langerhans Cell Histiocytosis (LCH)	V2.0.2025	PEDONC-18.2	LCH surveillance updated to include PET/CT imaging option in lieu of diagnostic CT or MRI; high-risk site involvement may have PET/CT in addition to other indicated diagnostic imaging studies	Yes, more approvals	No	Go RS, Jacobsen E, Baiocchi R, et. al. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2024 - January 7, 2025. Histiocytic Neoplasms, available at: https://www.nccn.org/professionals/physician_gl s/pdf/histiocytic_neoplasms.pdf
Langerhans Cell Histiocytosis (LCH)	V2.0.2025	PEDONC-18.2	Clarified wording of further brain imaging after two years	No	N/A	N/A
Non-Langerhans Cell Histiocytosis	V2.0.2025	PEDONC-18.4	Removed background and supporting language stating no established role for PET in Rosai-Dorfman disease	No	N/A	N/A